Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
Eric Van Cutsem(Universitair Ziekenhuis Leuven), Josep Tabernero(Deaconess Hospital), Alberto Sobrero(Ospedale Policlinico San Martino), Nikolaos Pavlidis(University Hospital of Ioannina), Atsushi Ohtsu(National Cancer Center Hospital East), Thomas Gruenberger(Sigmund Freud Privatuniversität Wien), Nadir Arber(Unknown), Jordan Berlin(Dana-Farber Cancer Institute), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Ravit Geva(Tel Aviv Sourasky Medical Center), Karin Haustermans(Radboud University Nijmegen), Aimery de Gramont(Institut Hospitalier Franco Britannique), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Bengt Glimelius(Uppsala University), Axel Grothey(Campbell Clinic), Roberto Labianca(Ospedale Papa Giovanni XXIII), Michel Ducreux(Université Paris-Saclay), Bruce D. Minsky(The University of Texas MD Anderson Cancer Center), Wolff Schmiegel(Universitätsklinikum Knappschaftskrankenhaus Bochum), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Andrés Cervantes(INCLIVA Health Research Institute), R. Glynne Jones(Mount Vernon Hospital), P. Rougier(Université de Versailles Saint-Quentin-en-Yvelines), Bernard Nordlinger(Académie Nationale de Médecine), CJH van de Velde(Leiden University Medical Center), Daniel G. Haller(University of Pennsylvania), M. Dicato(Centre Hospitalier de Luxembourg), Eduardo Díaz‐Rubio(Hospital Clínico San Carlos)
Cited by 80
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k